Side Effects of Rasonque (Daraxonrasib)
Rasonque causes skin reactions (rash), diarrhea, and mouth sores as the most common side effects, with approximately 96% of patients experiencing treatment-related adverse events of any grade and 30% experiencing grade 3 or higher toxicity. 1
Most Common Side Effects
The following adverse events occur most frequently in patients taking Rasonque 1:
- Rash (most common dermatologic toxicity)
- Diarrhea
- Stomatitis/mucositis (mouth sores and swelling)
- Nausea
- Fatigue or weakness
- Vomiting
- Abdominal pain
- Peripheral edema (swelling in arms and legs)
- Decreased appetite
- Bleeding
Additionally, abnormal blood test results are common and require monitoring by your healthcare provider 1.
Serious Side Effects Requiring Immediate Medical Attention
Severe Skin Reactions
Skin reactions can be severe and require prophylactic management 1:
- Red, swollen, painful skin around finger or toenails
- Severe rash, itching, dry or cracked skin
- Management requires: topical corticosteroids (face and chest), emollient creams, sun protection (SPF 30+), and prophylactic oral antibiotics (doxycycline or minocycline)
Severe Stomatitis
Mouth sores can become severe enough to interfere with eating, talking, or swallowing 1:
- Pain, redness, swelling, ulcers or sores in the mouth
- May require dose reduction or temporary treatment interruption for Grade 3 toxicity
Severe Diarrhea
Diarrhea requiring antidiarrheal treatment 1:
- Contact your provider if bowel movements increase by 6 or more per day
- Grade 3 diarrhea requires treatment interruption until recovery
Gastrointestinal Perforation
This is a potentially life-threatening complication 1:
- Severe or persistent abdominal pain/tenderness
- Nausea, vomiting, or vomiting blood
- Blood in stool or black tarry stools
- Fever or chills
- Requires permanent discontinuation
Interstitial Lung Disease (ILD)/Pneumonitis
Lung problems can be severe and potentially fatal 1:
- New or worsening cough
- Shortness of breath
- Trouble breathing or wheezing
Dose Modifications
The FDA label provides specific guidance for managing toxicity 1:
Dose reduction schedule:
- Standard dose: 300 mg once daily
- First reduction: 200 mg once daily
- Second reduction: 150 mg once daily
- Permanent discontinuation if unable to tolerate 150 mg
Grade 2 toxicity: Consider withholding until recovery to Grade ≤1, then resume at same or reduced dose
Grade 3 toxicity: Withhold until recovery to Grade ≤1, then resume at next lower dose level
Grade 4 toxicity: Permanently discontinue
Clinical Context
In the phase 3 RASolute 302 trial, treatment-related adverse events of grade 3 or higher occurred in 61.8% of daraxonrasib patients versus 69.6% with chemotherapy 2. Importantly, treatment discontinuation due to adverse events was substantially lower with daraxonrasib (1.2%) compared to chemotherapy (11.2%) 2, indicating that while side effects are common, they are generally manageable with appropriate dose modifications and supportive care.
Key Safety Precautions
Contraception requirements 1:
- Females of reproductive potential must use effective contraception during treatment and for 1 week after the last dose
- Males with female partners of reproductive potential must use effective contraception during treatment and for 1 week after the last dose
Pregnancy and breastfeeding 1:
- Can cause fetal harm; pregnancy testing required before starting treatment
- Do not breastfeed during treatment and for 1 week after the last dose
Drug interactions: Inform your healthcare provider of all medications, as Rasonque can interact with other drugs and increase side effect risk 1.